Compare Abbott Laboratories (ABT) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Grab Holdings Ltd. — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Grab Holdings Ltd. trades at $3.82 (market cap $16.07B). The key difference: Abbott Laboratories is far larger — about 10.4× Grab Holdings Ltd.'s market cap, and Abbott Laboratories pays a 2.63% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals.
| ABT | GRAB | |
|---|---|---|
Market Cap | $166.94B | $16.07B |
Sector | Health | Technology |
52-Week High | $136.62 | $6.45 |
52-Week Low | $82.57 | $3.27 |
Enterprise Value | $193.69B | $11.77B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
GRAB trades at $3.93, up 0.77% today, with a bullish technical signal from moving averages. The company achieved profitability in 2025 with net income of $268 million and revenue growth to $3.37 billion. Recent news highlights the departure of Uber's CEO from GRAB's board, causing a brief stock dip. Analyst consensus is strongly bullish with a $5.60 price target, representing significant upside potential from current levels.
GRAB's outlook is positive due to sustained revenue growth and recent profitability, though high P/E of 96.25 suggests elevated expectations. Key risks include competitive pressures in Southeast Asia and reliance on continued user growth. The stock offers growth exposure to the region's digital economy, supported by strong analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
